You are here
Public submissions on scheduling matters referred to the ACMS #29, ACCS #27 and Joint ACMS-ACCS #24 meetings held in March 2020
Scheduling of chemicals and poisons
Published
Public submissions made in response to the proposed amendments to the Poisons Standard published on 20 December 2019 and 6 January 2020 under regulation 42ZCZK of the Therapeutic Goods Regulations 1990 (the Regulations).
Public submissions on proposed amendments referred to an expert advisory committee
Public submissions on proposed amendments referred to the ACMS #29
*Large file warning: Attempting to open large files over the Internet within the browser window may cause problems. It is strongly recommended you download this document to your own computer and open it from there.
Ranitidine
- Consultation submission: Australian Medical Association (AMA) (pdf,214kb)
- Consultation submission: NSW Poisons Information Centre (NSW PIC) (pdf,247kb)
- Consultation submission: Pharmaceutical Society of Australia (PSA) (pdf,379kb)
- Consultation submission: The Pharmacy Guild of Australia (PGA) (pdf,604kb)*
Selective Serotonin Reuptake Inhibitor (SSRI) group entry
Fexofenadine
- Consultation submission: Australian Medical Association (AMA) (pdf,214kb)
- Consultation submission: NSW Poisons Information Centre (NSW PIC) (pdf,247kb)
- Consultation submission: Pharmaceutical Society of Australia (PSA) (pdf,379kb)
- Consultation submission: The Pharmacy Guild of Australia (PGA) (pdf,604kb)*
Flurbiprofen
- Consultation submission: Australian Medical Association (AMA) (pdf,214kb)
- Consultation submission: Consumer Healthcare Products (CHP) Australia (pdf,162kb)
- Consultation submission: NSW Poisons Information Centre (NSW PIC) (pdf,247kb)
- Consultation submission: Pharmaceutical Society of Australia (PSA) (pdf,379kb)
- Consultation submission: The Pharmacy Guild of Australia (PGA) (pdf,604kb)*
Ondansetron
- Consultation submission: Australian Medical Association (AMA) (pdf,214kb)
- Consultation submission: NSW Poisons Information Centre (NSW PIC) (pdf,247kb)
- Consultation submission: Pharmaceutical Society of Australia (PSA) (pdf,379kb)
- Consultation submission: The Pharmacy Guild of Australia (PGA) (pdf,604kb)*
- Consultation submission: The Society of Hospital Pharmacists of Australia (SHPA) (pdf,220kb)
Rizatriptan
- Consultation submission: Australian Medical Association (AMA) (pdf,214kb)
- Consultation submission: Consumer Healthcare Products (CHP) Australia (pdf,162kb)
- Consultation submission: NSW Poisons Information Centre (NSW PIC) (pdf,247kb)
- Consultation submission: Pharmaceutical Society of Australia (PSA) (pdf,379kb)
- Consultation submission: The Pharmacy Guild of Australia (PGA) (pdf,604kb)*
Melatonin
- Consultation submission: Aspen Australia (pdf,1.04Mb)
- Consultation submission: Australian Medical Association (AMA) (pdf,214kb)
- Consultation submission: Complementary Medicines Australia (CMA) (pdf,641kb)*
- Consultation submission: Consumer Healthcare Products (CHP) Australia (pdf,162kb)
- Consultation submission: NSW Poisons Information Centre (NSW PIC) (pdf,247kb)
- Consultation submission: Pharmaceutical Society of Australia (PSA) (pdf,379kb)
- Consultation submission: The Pharmacy Guild of Australia (PGA) (pdf,604kb)*
- Consultation submission: The Society of Hospital Pharmacists of Australia (SHPA) (pdf,220kb)
Adapalene
- Consultation submission: Australian Medical Association (AMA) (pdf,214kb)
- Consultation submission: Consumer Healthcare Products (CHP) Australia (pdf,162kb)
- Consultation submission: Ego Pharmaceuticals Pty Ltd (pdf,267kb)
- Consultation submission: Pharmaceutical Society of Australia (PSA) (pdf,379kb)
- Consultation submission: The Australasian College of Dermatologists (pdf,876kb)*
- Consultation submission: The Pharmacy Guild of Australia (PGA) (pdf,604kb)*
Public submissions on proposed amendments referred to the Joint ACMS-ACCS #24
Nicotine (Heated Tobacco Products)
- Consultation submission: ACT Health (pdf,154kb)
- Consultation submission: Andrew da Roza (pdf,134kb)
- Consultation submission: Andrew Thompson (pdf,901kb)*
- Consultation submission: Australian Chronic Disease Prevention Alliance (ACDPA) (pdf,241kb)
- Consultation submission: Australian Drug Law Reform Foundation (pdf,116kb)
- Consultation submission: Australian Medical Association (AMA) (pdf,214kb)
- Consultation submission: Australian Retail Vaping Industry Association (ARVIA) (pdf,730kb)*
- Consultation submission: Australian Tobacco Harm Reduction Association (pdf,561kb)*
- Consultation submission: Cancer Council Australia, National Heart Foundation of Australia, Australian Council on Smoking and Health (joint submission) (pdf,543kb)*
- Consultation submission: Consumer Healthcare Products (CHP) Australia (pdf,162kb)
- Individual - The submitter did not give permission to publish their name and their submission
- Individual - The submitter did not give permission to publish their name and their submission
- Individual - The submitter did not give permission to publish their name and their submission
- Individual - The submitter did not give permission to publish their name and their submission
- Individual - The submitter did not give permission to publish their name and their submission
- Individual - The submitter did not give permission to publish their name and their submission
- Consultation submission: Individual - The submitter did not give permission to publish their name (pdf,500kb)
- Consultation submission: Individual - The submitter did not give permission to publish their name (pdf,244kb)
- Consultation submission: Dr Kar Chan (pdf,744kb)*
- Consultation submission: Legalise Vaping Australia (pdf,8.53Mb)*
- Consultation submission: Lung Foundation Australia (pdf,488kb)
- Consultation submission: Lung Life Support Group (pdf,71kb)
- Consultation submission: Minderoo Foundation (pdf,511kb)*
- Consultation submission: NSW Poisons Information Centre (PIC) (pdf,212kb)
- Organisation - The submitter did not give permission to publish their name and their submission
- Organisation - The submitter did not give permission to publish their name and submission
- Consultation submission: Organisation - The submitter did not give permission to publish their name (pdf,231kb)
- Consultation submission: Pharmaceutical Society of Australia (PSA) (pdf,379kb)
- Consultation submission: Progressive Public Health Alliance (pdf,403kb)
- Consultation submission: Public Health Association of Australia (PHAA) (pdf,879kb)*
- Consultation submission: Royal Australian College of General Practitioners (pdf,177kb)
- Consultation submission: South Australian Health and Medical Research Institute and School of Public Health, University of Adelaide (pdf,268kb)
- Consultation submission: Stroke Foundation (pdf,564kb)*
- Consultation submission: The Pharmacy Guild of Australia (PGA) (pdf,604kb)*
- Consultation submission: The Thoracic Society of Australia and New Zealand (pdf,260kb)
- Consultation submission: Zhengde Hanyuan Technology Co.,Ltd. (pdf,43kb)
Pentobarbital
- Consultation submission: Animal Management in Rural and Remote Indigenous Communities (AMRRIC) (pdf,329kb)
- Consultation submission: Australian Medical Association (AMA) (pdf,214kb)
- Consultation submission: Australian Veterinary Association (pdf,268kb)
- Consultation submission: Dr Georgia Priest (pdf,65kb)
- Industry stakeholder - The submitter did not give permission to publish their name and submission
- Consultation submission: Individual - The submitter did not give permission to publish their name (pdf,190kb)
- Consultation submission: NSW Poisons Information Centre (PIC) (pdf,212kb)
- Consultation submission: Pharmaceutical Society of Australia (PSA) (pdf,379kb)
- Consultation submission: RSPCA QLD (pdf,205kb)
- Consultation submission: The Pharmacy Guild of Australia (PGA) (pdf,604kb)*
- Consultation submission: Veterinary Practitioners Board (pdf,143kb)
Marker dyes and pigments
Public submissions on proposed amendments referred to the ACCS #27
Arbutin
- Consultation submission: Accord (pdf,291kb)
- Consultation submission: Complementary Medicines Australia (CMA) (pdf,641kb)*
- Consultation submission: Integria Healthcare (pdf,901kb)*
- Consultation submission: Pharmaceutical Society of Australia (PSA) (pdf,379kb)
- Consultation submission: The Australasian College of Dermatologists (pdf,786kb)*
Picramic acid (including its salts)
Aclonifen
No submissions received
Carbetamide
No submissions received
Outcome of
- ACMS #29, March 2020
- ACCS #27, March 2020
- Joint ACMS-ACCS meeting #24, March 2020
- Consultation: Proposed amendments to the Poisons Standard - ACCS, ACMS and Joint ACMS/ACCS meetings, March 2020
- Consultation: Proposed amendments to the Poisons Standard - Joint ACCS/ACMS meetings, March 2020
- Advisory Committee on Medicines Scheduling (ACMS)
- Advisory Committee on Chemicals Scheduling (ACCS)